145 related articles for article (PubMed ID: 21633047)
1. Randomized phase II non-inferiority study (NO16853) of two different doses of capecitabine in combination with docetaxel for locally advanced/metastatic breast cancer.
Buzdar AU; Xu B; Digumarti R; Goedhals L; Hu X; Semiglazov V; Cheporov S; Gotovkin E; Hoersch S; Rittweger K; Miles DW; O'Shaughnessy J; Tjulandin S;
Ann Oncol; 2012 Mar; 23(3):589-597. PubMed ID: 21633047
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of low-dose capecitabine plus docetaxel versus single-agent docetaxel in patients with anthracycline-pretreated HER2-negative metastatic breast cancer: results from the randomized phase III JO21095 trial.
Yamamoto D; Sato N; Rai Y; Yamamoto Y; Saito M; Iwata H; Masuda N; Oura S; Watanabe J; Hattori S; Matsuura Y; Kuroi K
Breast Cancer Res Treat; 2017 Feb; 161(3):473-482. PubMed ID: 28005247
[TBL] [Abstract][Full Text] [Related]
3. Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial.
Gligorov J; Doval D; Bines J; Alba E; Cortes P; Pierga JY; Gupta V; Costa R; Srock S; de Ducla S; Freudensprung U; Mustacchi G
Lancet Oncol; 2014 Nov; 15(12):1351-60. PubMed ID: 25273343
[TBL] [Abstract][Full Text] [Related]
4. A Phase II trial of split, low-dose docetaxel and low-dose capecitabine: a tolerable and efficacious regimen in the first-line treatment of patients with HER2/neu-negative metastatic breast cancer.
Silva O; Lopes G; Morgenzstern D; Lobo C; Doliny P; Santos E; Abdullah S; Gautam U; Reis I; Welsh C; Slingerland J; Hurley J; Gluck S
Clin Breast Cancer; 2008 Apr; 8(2):162-7. PubMed ID: 18621613
[TBL] [Abstract][Full Text] [Related]
5. Detailed analysis of a randomized phase III trial: can the tolerability of capecitabine plus docetaxel be improved without compromising its survival advantage?
Leonard R; O'Shaughnessy J; Vukelja S; Gorbounova V; Chan-Navarro CA; Maraninchi D; Barak-Wigler N; McKendrick JJ; Harker WG; Bexon AS; Twelves C
Ann Oncol; 2006 Sep; 17(9):1379-85. PubMed ID: 16966367
[TBL] [Abstract][Full Text] [Related]
6. Randomized phase III trial comparing docetaxel plus epirubicin versus docetaxel plus capecitabine as first-line treatment in women with advanced breast cancer.
Mavroudis D; Papakotoulas P; Ardavanis A; Syrigos K; Kakolyris S; Ziras N; Kouroussis C; Malamos N; Polyzos A; Christophyllakis C; Kentepozidis N; Georgoulias V;
Ann Oncol; 2010 Jan; 21(1):48-54. PubMed ID: 19906761
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant capecitabine and docetaxel (plus trastuzumab): an effective non-anthracycline-based chemotherapy regimen for patients with locally advanced breast cancer.
Wildiers H; Neven P; Christiaens MR; Squifflet P; Amant F; Weltens C; Smeets A; van Limbergen E; Debrock G; Renard V; Van Eenoo L; Wynendaele W; Paridaens R
Ann Oncol; 2011 Mar; 22(3):588-594. PubMed ID: 20709813
[TBL] [Abstract][Full Text] [Related]
8. North Central Cancer Treatment Group (NCCTG) N0432: phase II trial of docetaxel with capecitabine and bevacizumab as first-line chemotherapy for patients with metastatic breast cancer.
Perez EA; Hillman DW; Dentchev T; Le-Lindqwister NA; Geeraerts LH; Fitch TR; Liu H; Graham DL; Kahanic SP; Gross HM; Patel TA; Palmieri FM; Dueck AC
Ann Oncol; 2010 Feb; 21(2):269-274. PubMed ID: 19901014
[TBL] [Abstract][Full Text] [Related]
9. A phase II trial of capecitabine and docetaxel followed by 5-fluorouracil/epirubicin/cyclophosphamide (FEC) as preoperative treatment in women with stage II/III breast cancer.
Jinno H; Sakata M; Hayashida T; Takahashi M; Mukai M; Ikeda T; Kitagawa Y
Ann Oncol; 2010 Jun; 21(6):1262-1266. PubMed ID: 19854722
[TBL] [Abstract][Full Text] [Related]
10. A multicentre phase II study to evaluate sequential docetaxel followed by capecitabine treatment in anthracycline-pretreated HER-2-negative patients with metastatic breast cancer.
Bayo J; Lomas M; Salvador J; Moreno A; Ruiz M; Rodríguez A; Fuentes J; Fernández-Freire A; Bernabé R; Fernández A
Clin Transl Oncol; 2008 Dec; 10(12):817-25. PubMed ID: 19068453
[TBL] [Abstract][Full Text] [Related]
11. Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer.
Chan S; Romieu G; Huober J; Delozier T; Tubiana-Hulin M; Schneeweiss A; Lluch A; Llombart A; du Bois A; Kreienberg R; Mayordomo JI; Antón A; Harrison M; Jones A; Carrasco E; Vaury AT; Frimodt-Moller B; Fumoleau P
J Clin Oncol; 2009 Apr; 27(11):1753-60. PubMed ID: 19273714
[TBL] [Abstract][Full Text] [Related]
12. A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer.
Martin M; Bonneterre J; Geyer CE; Ito Y; Ro J; Lang I; Kim SB; Germa C; Vermette J; Wang K; Wang K; Awada A
Eur J Cancer; 2013 Dec; 49(18):3763-72. PubMed ID: 23953056
[TBL] [Abstract][Full Text] [Related]
13. S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial.
Hong YS; Park YS; Lim HY; Lee J; Kim TW; Kim KP; Kim SY; Baek JY; Kim JH; Lee KW; Chung IJ; Cho SH; Lee KH; Shin SJ; Kang HJ; Shin DB; Jo SJ; Lee JW
Lancet Oncol; 2012 Nov; 13(11):1125-32. PubMed ID: 23062232
[TBL] [Abstract][Full Text] [Related]
14. Low-dose capecitabine plus docetaxel as first-line therapy for metastatic breast cancer: phase II results.
Michalaki V; Gennatas S; Gennatas K
Anticancer Drugs; 2009 Mar; 20(3):204-7. PubMed ID: 19174694
[TBL] [Abstract][Full Text] [Related]
15. Phase II gemcitabine and capecitabine combination therapy in recurrent or metastatic breast cancer patients pretreated with anthracycline and taxane.
Park JS; Jeung HC; Rha SY; Ahn JB; Kang B; Chon HJ; Hong MH; Lim S; Yang WI; Nam CM; Chung HC
Cancer Chemother Pharmacol; 2014 Oct; 74(4):799-808. PubMed ID: 25107569
[TBL] [Abstract][Full Text] [Related]
16. Effects on quality of life of weekly docetaxel-based chemotherapy in patients with locally advanced or metastatic breast cancer: results of a single-centre randomized phase 3 trial.
Nuzzo F; Morabito A; Gravina A; Di Rella F; Landi G; Pacilio C; Labonia V; Rossi E; De Maio E; Piccirillo MC; D'Aiuto G; Thomas R; Rinaldo M; Botti G; Di Bonito M; Di Maio M; Gallo C; Perrone F; de Matteis A
BMC Cancer; 2011 Feb; 11():75. PubMed ID: 21324184
[TBL] [Abstract][Full Text] [Related]
17. Final results of a phase II clinical trial of weekly docetaxel in combination with capecitabine in anthracycline-pretreated metastatic breast cancer.
Mackey JR; Tonkin KS; Koski SL; Scarfe AG; Smylie MG; Joy AA; Au HJ; Bodnar DM; Soulieres D; Smith SW
Clin Breast Cancer; 2004 Oct; 5(4):287-92. PubMed ID: 15507175
[TBL] [Abstract][Full Text] [Related]
18. Final results of ERASME-4: a randomized trial of first-line docetaxel plus either capecitabine or epirubicin for metastatic breast cancer.
Bachelot T; Bajard A; Ray-Coquard I; Provencal J; Coeffic D; Agostini C; Boisseau M; Kaphan R; Dramais D; Oprea C; Ferri-Dessens RM; Guastalla JP; Perol D
Oncology; 2011; 80(3-4):262-8. PubMed ID: 21734418
[TBL] [Abstract][Full Text] [Related]
19. Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study.
Van Cutsem E; Boni C; Tabernero J; Massuti B; Middleton G; Dane F; Reichardt P; Pimentel FL; Cohn A; Follana P; Clemens M; Zaniboni A; Moiseyenko V; Harrison M; Richards DA; Prenen H; Pernot S; Ecstein-Fraisse E; Hitier S; Rougier P
Ann Oncol; 2015 Jan; 26(1):149-156. PubMed ID: 25416687
[TBL] [Abstract][Full Text] [Related]
20. Thymidine phosphorylase expression is associated with time to progression in patients receiving low-dose, docetaxel-modulated capecitabine for metastatic breast cancer.
Puglisi F; Cardellino GG; Crivellari D; Di Loreto C; Magri MD; Minisini AM; Mansutti M; Andreetta C; Russo S; Lombardi D; Perin T; Damante G; Veronesi A
Ann Oncol; 2008 Sep; 19(9):1541-6. PubMed ID: 18441329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
